STOCK TITAN

Zoar completes 1-for-1 merger with Impact Biomedical

Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
6-K

Rhea-AI Filing Summary

Zoar Limited completed its business combination on November 17, 2026, combining with Impact Biomedical and acquiring all issued and outstanding shares of Zoar Labs from its sole shareholder, Dr. Kanans Visvanats, in exchange for Zoar ordinary shares. Impact survived as a wholly owned subsidiary, renamed Zoar USA Inc., and each Impact common share was converted into the right to receive one Zoar ordinary share. Zoar shares were expected to begin trading on NYSE American under ZOAR on November 18, 2026.

For the fiscal year ended March 31, 2026, Zoar Labs reported revenue of $651.7 million, up approximately 17.1% from $556.4 million in the prior fiscal year, and net income of $77.7 million, up approximately 23.9% from $62.7 million. Following the transaction, Zoar had approximately 180.0 million ordinary shares outstanding; Dr. Visvanats held approximately 93.32% and former Impact stockholders held approximately 4.80%. Zoar develops and manufactures active pharmaceutical ingredients and intermediates and provides contract development and manufacturing services. Its products are sold to customers in over 35 countries.

2 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 0 points

How the balance works

Positive

  • Moderate pointZoar Labs revenue rose approximately 17.1% to $651.7 million in fiscal 2026.
  • Moderate pointZoar Labs net income rose approximately 23.9% to $77.7 million in fiscal 2026.

Negative

  • None.
Revenue $651.7 million Zoar Labs, fiscal year ended March 31, 2026; up approximately 17.1% from $556.4 million in the prior fiscal year.
Net income $77.7 million Zoar Labs, fiscal year ended March 31, 2026; up approximately 23.9% from $62.7 million in the prior fiscal year.
Ordinary shares outstanding Approximately 180.0 million shares Zoar following completion of the business combination.
Zoar Shareholder ownership Approximately 93.32% Following completion of the business combination.
Former Impact stockholders' ownership Approximately 4.80% Following completion of the business combination.
Share exchange One Zoar ordinary share for each Impact common share Each Impact common share converted into the right to receive one Zoar ordinary share.
active pharmaceutical ingredients (APIs) medical
"development and manufacturing of active pharmaceutical ingredients (APIs)"
Active pharmaceutical ingredients (APIs) are the chemical or biological substances in a medicine that produce the intended therapeutic effect — think of them as the engine inside a car that makes it run. Investors care because API supply, quality, cost, and intellectual property control determine a drug maker’s ability to sell medicines, meet regulatory requirements, and protect profit margins; disruptions or shortages can quickly affect revenue and stock value.
contract development and manufacturing (CDMO) services technical
"provides contract development and manufacturing (CDMO) services"
contract manufacturing organizations technical
"collaboration with selected contract manufacturing organizations"
orphan drug APIs medical
"expanding our product offering in orphan drug APIs"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many Zoar shares did former Impact stockholders receive for each Impact share?

Each Impact common share was converted into the right to receive one Zoar ordinary share. Impact survived the merger as a wholly owned Zoar subsidiary, renamed Zoar USA Inc.

What were Zoar Labs' revenue and net income for fiscal 2026?

Zoar Labs reported $651.7 million in revenue and $77.7 million in net income for the fiscal year ended March 31, 2026. In the prior fiscal year, revenue was $556.4 million and net income was $62.7 million.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 OF THE

SECURITIES EXCHANGE ACT OF 1934

 

For the month of November 2026

 

Commission File Number 001-43544

 

Zoar Limited

(Translation of registrant’s name into English)

 

1504, 15th Floor, Peninsula Square

18 Sung On Street, Hung Hom,

Kowloon, Hong Kong

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

 

Form 20-F ☒          Form 40-F ☐

 

 

 

 

 

 

Completion of Merger and Commencement of Trading

 

On November 17, 2026, Zoar Limited (the “Company”) consummated the previously announced business combination pursuant to the merger and share exchange agreement, dated as June 21, 2025, as amended, involving the Company, Impact Biomedical Inc., Zoar Labs Limited, Dr Ashleys Nevada Sub, Inc. and Kanas Visvanats (the “Business Combination”).

 

In connection with the completion of the Business Combination, the Company’s ordinary shares are expected to commence trading on the NYSE American under the ticker symbol “ZOAR” on November 18, 2026.

 

On November 18, the Company issued a press release announcing the completion of the Business Combination and the commencement of trading, a copy of which is furnished as Exhibit 99.1 hereto.

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Date: November 18, 2026 Zoar Limited
     
  By: /s/ Kanans Visvanats
    Kanans Visvanats
    Chief Executive Officer

 

2

 

 

EXHIBIT INDEX

 

Exhibit No.   Description
99.1   Press release, dated November 18, 2026.

 

3

 

Exhibit 99.1

 

 

Zoar Limited Completes Business Combination with Impact Biomedical Inc.

 

Zoar Limited ordinary shares are expected to begin trading on the NYSE American under the ticker symbol “ZOAR” on November 18, 2026.

 

The Business Combination was approved by Impact Biomedical Inc.’s stockholders at a special meeting held on November 13, 2026.

 

Zoar Labs, Zoar’s operating subsidiary, reported revenue of $651.7 million and net income of $77.7 million for the fiscal year ended March 31, 2026.

 

Hong Kong, November 18, 2026 — Zoar Limited (NYSE American: ZOAR) (“Zoar” or the “Company”), a global pharmaceutical company focused on the development and manufacturing of complex active pharmaceutical ingredients (“APIs”) and intermediates, today announced that it has completed its business combination involving the Company, Impact Biomedical Inc. (“Impact”), Dr Ashleys Nevada Sub Inc. and Zoar Labs Limited (“Zoar Labs”) (the “Business Combination”). Zoar’s ordinary shares are expected to begin trading on NYSE American under the ticker symbol “ZOAR” on November 18, 2026. In connection with the completed Business Combination, each share of Impact common stock, which traded on the NYSE American under the ticker symbol “IBO,” was converted into the right to receive one Zoar ordinary share.

 

“Completing this business combination and listing on NYSE American is an important milestone for Zoar and for the customers and partners who have supported us since our founding in 2012,” said Dr. Kanans Visvanats, Founder, Chairman, and Chief Executive Officer of Zoar. “Over that time, we have grown into a supplier of APIs and intermediates to customers in more than 35 countries. We believe that access to the U.S. capital markets will give us greater visibility with customers and investors, as well as additional flexibility to pursue our growth strategy, including expanding our product offering in orphan drug APIs. I would like to thank the Impact team for their partnership in bringing this transaction to completion, and we look forward to engaging with our new shareholders as a public company.”

 

Zoar develops, manufactures, and distributes active pharmaceutical ingredients (APIs) and intermediates in collaboration with selected contract manufacturing organizations, and provides contract development and manufacturing (“CDMO”) services for complex APIs and intermediates in specialized therapeutic areas. Its products span six therapeutic categories (anti-cancer, anti-coagulants, anti-malarial, anti-viral, bronchodilators, and anti-respiratory) and are sold directly and through a network of approximately 100 distributors and pharmaceutical partners across Europe, Africa, the Middle East, India, Asia, and Central and South America.

 

For the fiscal year ended March 31, 2026, Zoar Labs, a wholly owned subsidiary of the Company, reported revenue of $651.7 million compared to $556.4 million in the prior fiscal year, an increase of approximately 17.1%. Net income for the fiscal year ended March 31, 2026 was $77.7 million compared to $62.7 million in the prior fiscal year, an increase of approximately 23.9%.

 

The Business Combination was completed pursuant to the Merger and Share Exchange Agreement dated June 21, 2025, as amended. Under its terms, a wholly owned subsidiary of Zoar merged with and into Impact, with Impact surviving as a wholly owned subsidiary of Zoar and being renamed Zoar USA Inc., and Zoar acquired all of the issued and outstanding shares of Zoar Labs from its sole shareholder, Dr. Visvanats (the “Zoar Shareholder”), in exchange for Zoar ordinary shares. Following the completion of the Business Combination, Zoar has approximately 180.0 million ordinary shares outstanding, of which Zoar Shareholder held approximately 93.32%, and former Impact stockholders held approximately 4.80%.

 

 

 

 

 

Zoar is led by Dr. Kanans Visvanats, Chairman and Chief Executive Officer; Adrian Anthony Simon Markland, Chief Operating Officer; and Sameer Ramesh Talim, Head of Sales and Marketing. The Company’s Board of Directors consists of eight members: Dr. Visvanats (Chairman), Donald Kalkofen, Michael Zajas, Evan Lim, Neha Kumari, Maduabuchi Nelson Okey, Bang-Ning (Simon) Liu, and David A. Sanders.

 

Robinson & Cole LLP served as U.S. legal counsel, Harney Westwood & Riegels served as Cayman Islands legal counsel, Wong Poon Chan Law & Co. served as Hong Kong legal counsel, Marcum Asia CPAs LLP served as auditor, and BMI Capital International LLC served as advisor to Zoar. Sichenzia Ross Ference Carmel LLP served as legal counsel and Grassi & Co., CPAs, P.C. served as auditor to Impact.

 

About Zoar Limited

 

Zoar Limited is a global pharmaceutical company focused on the development and manufacturing of active pharmaceutical ingredients and provides contract development and manufacturing services to pharmaceutical and biotechnology companies worldwide. Zoar Limited currently offers more than 35 pharmaceutical products to customers in over 35 countries.

 

Forward-Looking Statements

 

This press release contains “forward-looking statements” that involve substantial risks and uncertainties. All statements other than statements of historical fact are forward-looking statements. These statements may be identified by words such as “may,” “could,” “will,” “should,” “would,” “expect,” “plan,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “project,” or “continue,” or the negative of these terms or other comparable terminology. Forward-looking statements in this press release include, but are not limited to, statements regarding the expected commencement of trading of Zoar Limited’s ordinary shares on the NYSE American; the anticipated benefits of the business combination; Zoar’s plans and strategies for growth, including any plans to expand its product offering to include orphan drugs; and the expected benefits of access to the U.S. capital markets.

 

These forward-looking statements are based on assumptions and on the current expectations of Zoar’s management and are not predictions of actual performance. You should not place undue reliance on these statements because they are subject to risks, uncertainties, and other factors, many of which are beyond Zoar’s control, that could cause actual events or results to differ materially from those expressed or implied by the forward-looking statements. These risks and uncertainties include, among others, risks relating to the completion and integration of the business combination and the realization of its anticipated benefits; Zoar’s ability to execute its business and growth strategies; the development, regulatory status, manufacture, quality, and commercialization of pharmaceutical products; Zoar’s reliance on contract manufacturing organizations and other third parties; customer demand, competition, and market conditions; supply-chain and operational disruptions; and the other risks described in Zoar’s filings with the U.S. Securities and Exchange Commission (the “SEC”).

 

These risks, uncertainties and other factors are, in some cases, beyond the Company’s control and could materially affect results. If one or more of these risks, uncertainties or other factors become applicable, or if these underlying assumptions prove to be incorrect, actual events or results may vary significantly from those implied or projected by the forward-looking statements. No forward-looking statement is a guarantee of future performance. Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no duty to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware, except as required under applicable law.

 

Investor Relations Contact

 

Gateway Group, Inc.

(949) 574-3860

ZOAR@gateway-grp.com

 

 

Filing Exhibits & Attachments

2 documents

Keep reading